MeiraGTx Holdings plc Lessee, Operating Lease, Liability, to be Paid, after Year Five
MeiraGTx Holdings plc (MGTX) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $4.20 million as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-05-14
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $4.20M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $4.20M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $6.05M.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $735.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.20M 10-K · filed 2026-03-30 |
| 2025-09-30 | $6.05M 10-Q · filed 2025-11-13 |
| 2024-09-30 | $735.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $692.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $691.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $706.00K 10-K · filed 2024-03-15 |
| 2023-09-30 | $2.88M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.97M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.92M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.87M 10-K · filed 2023-03-14 |
| 2021-12-31 | $4.25M 10-K · filed 2022-03-10 |
| 2020-12-31 | $7.15M 10-K · filed 2021-03-11 |
| 2020-09-30 | $9.84M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $10.49M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $10.53M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $10.71M 10-K · filed 2020-03-11 |
| 2019-09-30 | $14.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $9.19M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.23M 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |